{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:46:23Z","timestamp":1760298383245,"version":"3.44.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1053\/j.seminhematol.2011.06.001","type":"journal-article","created":{"date-parts":[[2011,7,25]],"date-time":"2011-07-25T03:35:15Z","timestamp":1311564915000},"page":"185-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prognostic Relevance of Clinical Risk Factors in Mantle Cell Lymphoma"],"prefix":"10.1053","volume":"48","author":[{"given":"Eva","family":"Hoster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2011.06.001_bib1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2011.06.001_bib2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.06.001_bib3","first-page":"138","article-title":"Confirmation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) in an independent prospective patient cohort","volume":"114","author":"Hoster","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.06.001_bib4","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3324\/haematol.2009.021113","article-title":"Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting","volume":"95","author":"van de Schans","year":"2010","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2011.06.001_bib5","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.06.001_bib6","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1182\/blood-2008-05-155507","article-title":"Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD","volume":"112","author":"Shah","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.06.001_bib7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with rituximab\u2013HyperCVAD alternating with rituximab\u2013high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2011.06.001_bib8","first-page":"1784","article-title":"Retrospective analysis of 206 mantle cell lymphoma patients at diagnosis: Mantle Cell International Prognostic Index (MIPI) is a good predictor of death event in patients treated either with rituximab-chemotherapy or rituximab-high-dose-chemotherapy","volume":"116","author":"Chiappella","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.06.001_bib9","first-page":"3745","article-title":"Mantle Cell Lymphoma International Prognostic Score is valid and confirmed in unselected cohort of patients treated in rituximab era","volume":"112","author":"Salek","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.06.001_bib10","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1080\/10428190903186494","volume":"50","author":"Eve","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2011.06.001_bib11","first-page":"2928","article-title":"Mantle Cell International Prognostic Index (MIPI) is a strong predictor of the outcome of mantle cell lymphoma (MCL) in the rituximab (R) era","volume":"114","author":"Chiappella","year":"2009","journal-title":"ASH Annual Meeting Abstracts"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196311000527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196311000527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:20:49Z","timestamp":1758522049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196311000527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0037196311000527"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2011.06.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Relevance of Clinical Risk Factors in Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2011.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}